| Literature DB >> 26246466 |
Felicitas Hitz1,2,3, J M Connors4, R D Gascoyne4,5, P Hoskins4, A Moccia4,6, K J Savage4, L H Sehn4, T Shenkier4, D Villa4, R Klasa4.
Abstract
Primary refractory diffuse large B cell lymphoma (DLBCL) following R-CHOP chemotherapy is a major concern. We identified 1126 patients with DLBCL treated with R-CHOP from 2000 to 2009, of whom 166 (15 %) had primary refractory disease. Of the 75/166 (45 %) who were age <70 years and had been planned for stage-directed curative therapy, 43 (57 %) were primary nonresponders and 32 (43 %) relapsed within 3 months of completing R-CHOP. Thirty of 75 (40 %) patients had serious comorbidity and organ dysfunction precluding intensive treatment and had palliative treatment only. Twelve of 45 (27 %) patients responded to second-line treatment and underwent ASCT. The median overall survival for the 75 patients was 10 months with only seven patients alive without evidence of disease at follow-up ranging from 14 to 106 months. Primary refractory DLBCL after R-CHOP has a very poor outcome with only anecdotal survivors independent of the intended treatment approach.Entities:
Keywords: Comorbidity; Diffuse large B cell lymphoma; Primary refractory; R-CHOP
Mesh：
Substances：
Year: 2015 PMID： 26246466 DOI： 10.1007/s00277-015-2467-z
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673